* Relay Therapeutics Inc RLAY.OQ reported a quarterly
adjusted
loss of 63 cents per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -54 cents. The mean expectation of twelve analysts for
the quarter was for a loss of 77 cents per share. Wall Street
expected results to range from -81 cents to -70 cents per share.
* Reported revenue was zero; analysts expected $80.00
thousand.
* Relay Therapeutics Inc's reported EPS for the quarter was
a loss
of 63 cents.
* The company reported a quarterly loss of $88.11 million.
* Relay Therapeutics Inc shares had fallen by 16.0% this
quarter and lost 46.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 1.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Relay
Therapeutics Inc is 20.50
This summary was machine generated from LSEG data November 7 at
04:41 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.77 -0.63 Beat
Jun. 30 2024 -0.73 -0.69 Beat
Mar. 31 2024 -0.70 -0.62 Beat
Dec. 31 2023 -0.73 -0.67 Beat